Saltar al contenido
Merck
Todas las fotos(2)

Documentos

GF01141333

Ruthenium

Ruthenium, microfoil, disks, 10mm, thinness 0.1μm, specific density 122μg/cm2, permanent mylar 3.5μm support, 99.9%

Sinónimos:

Ruthenium, RU004500

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula empírica (notación de Hill):
Ru
Número de CAS:
7440-18-8
Peso molecular:
101.07
MDL number:
MFCD00011207
UNSPSC Code:
12141739
PubChem Substance ID:
329800163
NACRES:
NA.23

assay

≥99.9%

form

foil

manufacturer/tradename

Goodfellow 011-413-33

resistivity

7.1 μΩ-cm, 0°C

diam. × thickness

10 mm × 0.1 μm

bp

3900 °C (lit.)

mp

2310 °C (lit.)

density

12.45 g/cm3 (lit.)

SMILES string

[Ru]

InChI

1S/Ru

Inchi Key

KJTLSVCANCCWHF-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

For updated SDS information please visit www.goodfellow.com.

Legal Information

Product of Goodfellow

Storage Class

13 - Non Combustible Solids

wgk_germany

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

E Tfouni et al.
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Aviva Levina et al.
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
A Bergamo et al.
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
Martin R Gill et al.
Chemical Society reviews, 41(8), 3179-3192 (2012-02-09)
In the last few decades, coordination complexes based on d(6) metal centres and polypyridyl ligand architectures been developed as structure- and site-specific reversible DNA binding agents. Due to their attractive photophysical properties, much of this research has focused on complexes
Lutz Ackermann et al.
Topics in current chemistry, 292, 211-229 (2010-01-01)
Stoichiometric cycloruthenation reactions of substrates containing Lewis-basic functionalities set the stage for efficient ruthenium-catalyzed C-H bond functionalization reactions. Thereby, selective addition reactions of C-H bonds across alkenes or alkynes enabled atom-economical synthesis of substituted arenes. More recently, ruthenium-catalyzed direct arylation
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico